What's Happening?
ImmunityBio, Inc. has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for ANKTIVA in combination with Bacillus Calmette-Guerin (BCG) for treating patients with BCG-unresponsive
non-muscle invasive bladder cancer (NMIBC) with papillary disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of January 6, 2027. This acceptance follows a public workshop by the FDA, where experts discussed the biological similarities between carcinoma in situ (CIS) and papillary disease, supporting the potential expansion of ANKTIVA's indication. The sBLA is backed by data from the QUILT 3.032 Phase 2/3 trial, which showed promising results in disease-free survival and bladder preservation.
Why It's Important?
The acceptance of this sBLA is significant as it could expand treatment options for patients with BCG-unresponsive NMIBC, a condition with limited bladder-sparing therapies. If approved, ANKTIVA plus BCG could become a crucial immunotherapy option, potentially reducing the need for radical cystectomy, a procedure associated with high morbidity. This development could also enhance ImmunityBio's market position in the NMIBC treatment landscape, offering a chemotherapy-free alternative that aligns with current real-world treatment practices. The decision could impact insurance reimbursement policies, making the treatment more accessible to patients.
What's Next?
The FDA will review the scientific data supporting the sBLA, focusing on the extrapolation of results from CIS to papillary disease. ImmunityBio will continue to engage with the FDA during this review process. If the sBLA is approved, it could lead to broader access to ANKTIVA plus BCG for patients with papillary-only disease, potentially influencing treatment guidelines and insurance coverage. The outcome of this review could also set a precedent for future applications involving similar biological overlaps in cancer treatment.
